Market Overview
According to fortune business insights, the global personalized medicine market size was valued at USD 214.44 billion in 2025. The market is projected to grow from USD 233.87 billion in 2026 to USD 587.02 billion by 2034, exhibiting a CAGR of 12.19% during the forecast period. North America dominated the personalized medicine market with a market share of 39.11% in 2025.
These insights have been deep-dived into in a recent research report, titled “Personalized Medicine Market, 2026-2034.”
The analysis shows that top companies are investing more in personalized medicine because of wider acceptance of genomic testing and heightened demand for biomarker-driven targeted therapies. For example, major players like F. Hoffmann-La Roche Ltd and Thermo Fisher Scientific Inc. are focusing on extensive genomic profiling, liquid biopsy, and AI-driven data platforms. This trend indicates strong demand for personalized medicine worldwide.
Major Players Profiled in the Market Report:
Segments
Expanding Use of Biomarker-Guided Therapies to Propel Therapeutics Segment Growth
Based on offering, the market is divided into diagnostics & testing, therapeutics, software & data analytics, and others. The therapeutics segment holds the largest market share and dominates the market owing to the high commercial potential of targeted therapies and the growing adoption of biomarker-driven treatment selection.
Wider Use of Genomic Profiling to Drive Genomics & Molecular Testing Segment Expansion
By technology, the market is categorized into genomics & molecular testing, biomarker-based profiling, liquid biopsy, and others. The genomics & molecular testing segment is leading the market as it plays a central role in identifying disease-causing mutations and therapy-response markers before treatment begins.